Micrus Endovascular enters Japan
This article was originally published in The Gray Sheet
Executive Summary
Japan's Ministry of Health, Labor & Welfare (MHLW) clears firm to sell MicruSphere, HeliPaq and InterPaq embolic coils to treat cerebral aneurysms. The firm hopes to convert the Japanese market from craniotomy - used on 75% of aneurysms - to coiling. According to Micrus, nearly one third of all interventional cerebral vascular disease treatment revenue comes from Japan. Following the clearance, the firm announced that it would work with Japanese distributor Goodman to clear further products in Japan, including the Cerecyte microcoil. The firm also plans to enter the Chinese market by June. One year ago, the firm noted that it would use proceeds from its $57.5 mil. initial public offering to break in to the Japanese market (1"The Gray Sheet" March 14, 2005, p. 31)...
You may also be interested in...
Micrus IPO To Fund Japan Aneurysm Coil Market Entry, Bioactive Coil R&D
Micrus will establish a Japanese distribution network later this year with proceeds from an initial public offering of up to $57.5 mil. in common stock
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.